US Patent Issued to GeneCentric Therapeutics, The University of North Carolina at Chapel Hill on Sept. 29 for "Methods for selecting and treating cancer with FGFR3 inhibitors" (North Carolina Inventors)

ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,748,103, issued on Sept. 29, was assigned to GeneCentric Therapeutics Inc. (Durham, N.C.) and The University of North Carolina at Chapel Hill (Chapel Hill, N.C.).

"Methods for selecting and treating cancer with FGFR3 inhibitors" was invented by Michael Milburn (Durham, N.C.), Gregory Mayhew (Durham, N.C.), Joel Eisner (Durham, N.C.) and Charles Perou (Carrboro, N.C.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are FGFR3 activation signatures for use in methods and compositions for predicting the response of a subject suffering from cancer to FGFR3 inhibitor therapy."

The patent was filed on June 22, 2021, under Application No. 18/002...